These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


177 related items for PubMed ID: 8678491

  • 1. [Progress of endocrine therapy for prostate cancer and results].
    Kanetake H.
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):413-7. PubMed ID: 8678491
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Total androgen blockade for prostate cancer].
    Kagebayashi Y, Ozono S, Takashima K, Yoshikawa M, Hayashi Y, Kaneko Y, Maruyama Y, Hirao Y, Okajima E.
    Hinyokika Kiyo; 1997 Mar; 43(3):197-201. PubMed ID: 9127754
    [Abstract] [Full Text] [Related]

  • 4. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W, Mattelaer J, Casselman J, Van Velthoven R, Derde MP, Kaufman L.
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [Abstract] [Full Text] [Related]

  • 5. [Total androgen blockade--concept, theory, method and clinical application].
    Ozono S, Hirao Y.
    Nihon Rinsho; 1998 Aug; 56(8):2129-34. PubMed ID: 9750521
    [Abstract] [Full Text] [Related]

  • 6. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H, Chodak GW, Hirao Y.
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 9. Endocrine therapy for prostate cancer.
    Damber JE.
    Acta Oncol; 2005 Sep; 44(6):605-9. PubMed ID: 16165920
    [Abstract] [Full Text] [Related]

  • 10. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H, Katayose K, Kumakawa K, Shiraiwa Y, Uchida H, Takahashi Y, Yazaki J, Yamaguchi O.
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 12. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J.
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract] [Full Text] [Related]

  • 13. [Total androgen blockade].
    Namiki M, Mizokami A.
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract] [Full Text] [Related]

  • 14. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group.
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [Abstract] [Full Text] [Related]

  • 15. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 16. Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients.
    Oosterlinck W, Mattelaer J, Derde MP, Kaufman L.
    Acta Urol Belg; 1995 Sep; 63(3):1-9. PubMed ID: 7484516
    [Abstract] [Full Text] [Related]

  • 17. Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer.
    Homma Y, Akaza H, Okada K, Yokoyama M, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group.
    Int J Urol; 2004 Apr; 11(4):218-24. PubMed ID: 15028100
    [Abstract] [Full Text] [Related]

  • 18. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T, Aizawa T, Yamamoto S, Ohkubo Y, Tsujino S, Miki M.
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [Abstract] [Full Text] [Related]

  • 19. Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significance.
    Normand G, Celhay O, Briffaux R, Pirès C, Doré B, Fromont G, Irani J.
    Urol Int; 2009 Jul; 83(2):160-5. PubMed ID: 19752610
    [Abstract] [Full Text] [Related]

  • 20. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.